Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Comprehensive analysis of the role of NLRC5 in gastrointestinal cancer: a systematic review

Universa Medicina · Vol. 43 No. 2 (2024) · hlm. 229–239

DOI
10.18051/UnivMed.2024.v43.229-239
ISSN
2407-2230, 1907-3062
Terbit
2024-06-11
Penerbit
Faculty of Medicine, Universitas Trisakti
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0

Abstrak

BackgroundGastrointestinal (GI) cancer is affecting millions of people globally, leading to high incidence and mortality rates and a heavy economic burden. Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are a family of cytosolic pattern recognition receptors that regulate host defense responses against microorganisms. Among these, NLR family CARD domain-containing 5 (NLRC5) is assumed to function as a regulator of proinflammatory responses to intracellular pathogens. NLRC5 has been known to regulate immune responses, although its association with cancer remains controversial. This systematic review aimed to explore the roles and functions of NLRC5 in GI cancers. MethodsThree electronic databases, PubMed, Scopus, and ProQuest, were used for literature searching on March 18, 2024. From 921 articles found, 157 duplicates were removed, 671 were excluded based on title and abstract screening, and 84 were excluded based on full-text assessment, resulting in 19 articles included in this review. ResultsElevated NLRC5 levels have been observed in tumor tissues compared to normal tissues across esophageal, gastric, colorectal, and liver cancers. NLRC5 is also associated with increased tumor cell proliferation, migration, and invasion. Cancer cell sensitivity to 5-fluorouracil chemotherapy was found to be negatively correlated with NLRC5 expression. NLRC5 expression levels and genetic variations were also associated with cancer susceptibility to chemotherapeutic drugs and cancer survival. ConclusionNLRC5 potentially exhibits diverse functions in GI cancers, acting as a biomarker for diagnosis, disease progression, prognostic assessment, and determining therapeutic implications. Further investigations are warranted to explore these mechanisms and their potentials for the development of effective treatment of GI cancers.

Kata kunci

Jaringan kolaborasi para penulis

8 penulis · 12 tautan kepenulisan bersama · 5 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Padjadjaran University
  • Sebelas Maret University
  • Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo
  • Universitas Gadjah Mada
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Erick KhristianPadjadjaran University1
Ratu SafitriPadjadjaran University1
Muhammad Hasan BashariPadjadjaran University1
Hamzah Haryo PrakosoSebelas Maret University1
Andre SetiawanSebelas Maret University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://univmed.org/ejurnal/index.php/medicina/oai, pertama di-harvest 10 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Comprehensive analysis of the role of NLRC5 in gastrointestinal cancer: a systematic review</dc:title>
	<dc:creator xml:lang="en">Rahadiani, Nur</dc:creator>
	<dc:creator xml:lang="en">Ghozali, Mohammad</dc:creator>
	<dc:creator xml:lang="en">Dewi, Dyah Laksmi</dc:creator>
	<dc:subject xml:lang="en">Biomarker</dc:subject>
	<dc:subject xml:lang="en">gastrointestinal cancer</dc:subject>
	<dc:subject xml:lang="en">GI cancer</dc:subject>
	<dc:subject xml:lang="en">NLRC5</dc:subject>
	<dc:subject xml:lang="en">diagnostic</dc:subject>
	<dc:subject xml:lang="en">prognostic</dc:subject>
	<dc:description xml:lang="en">BackgroundGastrointestinal (GI) cancer is affecting millions of people globally, leading to high incidence and mortality rates and a heavy economic burden. Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are a family of cytosolic pattern recognition receptors that regulate host defense responses against microorganisms. Among these, NLR family CARD domain-containing 5 (NLRC5) is assumed to function as a regulator of proinflammatory responses to intracellular pathogens. NLRC5 has been known to regulate immune responses, although its association with cancer remains controversial. This systematic review aimed to explore the roles and functions of NLRC5 in GI cancers.
MethodsThree electronic databases, PubMed, Scopus, and ProQuest, were used for literature searching on March 18, 2024. From 921 articles found, 157 duplicates were removed, 671 were excluded based on title and abstract screening, and 84 were excluded based on full-text assessment, resulting in 19 articles included in this review.
ResultsElevated NLRC5 levels have been observed in tumor tissues compared to normal tissues across esophageal, gastric, colorectal, and liver cancers. NLRC5 is also associated with increased tumor cell proliferation, migration, and invasion. Cancer cell sensitivity to 5-fluorouracil chemotherapy was found to be negatively correlated with NLRC5 expression. NLRC5 expression levels and genetic variations were also associated with cancer susceptibility to chemotherapeutic drugs and cancer survival.
ConclusionNLRC5 potentially exhibits diverse functions in GI cancers, acting as a biomarker for diagnosis, disease progression, prognostic assessment, and determining therapeutic implications. Further investigations are warranted to explore these mechanisms and their potentials for the development of effective treatment of GI cancers.</dc:description>
	<dc:publisher xml:lang="en">Faculty of Medicine, Universitas Trisakti</dc:publisher>
	<dc:date>2024-06-11</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://univmed.org/ejurnal/index.php/medicina/article/view/1545</dc:identifier>
	<dc:identifier>10.18051/UnivMed.2024.v43.229-239</dc:identifier>
	<dc:source xml:lang="en">Universa Medicina; Vol. 43 No. 2 (2024); 229-239</dc:source>
	<dc:source>2407-2230</dc:source>
	<dc:source>1907-3062</dc:source>
	<dc:source>10.18051/UnivMed.2024.v43.i2</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://univmed.org/ejurnal/index.php/medicina/article/view/1545/781</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Nur Rahadiani, Mohammad Ghozali, Dyah Laksmi Dewi</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>